Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on Wednesday, 11th January 2017 in the Boardroom at Hillder House

MEMBERS:

Dr M Ghani (Chair)	Medical Director (Barnsley CCG)
Dr R Hirst	Palliative Care Consultant (Barnsley Hospice)
Ms S Hudson	Lead Pharmacist (SWYPFT)
Dr K Kapur	Consultant Gastroenterology (BHNFT)
Ms C Lawson	Head of Medicines Optimisation (Barnsley CCG)
Dr K Sands	Clinical Lead (SWYPFT)
Mr M Smith	Chief Pharmacist (BHNFT)

IN ATTENDANCE:

Ms C Applebee	Medicines Management Pharmacist (Barnsley CCG)
Ms N Brazier	Administration Officer (Barnsley CCG)
Mr M Gawne	Medical Student
Mr F Hussain	Lead Pharmacist, Medicines Information & Cardiology (BHNFT)
Mr U Patel	Acting Formulary/Interface Pharmacist (BHNFT)

APOLOGIES:

Mr T Bisset	Community Pharmacist (LPC)
Mr N Heslop	Lead Pharmacist (Barnsley CCG)
Dr J Maters	General Practitioner (LMC)
Dr A Munzar	General Practitioner (LMC)

ACTION BY AND DEADLINE

APC 17/01 QUORACY

The meeting was not quorate. The Chair took the decision to continue with the meeting as planned but noted any decisions/approvals must be ratified at the next meeting.

APC 17/02 DECLARATIONS OF INTEREST RELEVANT TO THE AGENDA

No declarations of interest to note relevant to this agenda but Dr Kapur would be submitting an up to date declaration of interest. **KK/NB**

APC 17/03 MINUTES OF 7th DECEMBER 2016 MEETING

The minutes of the meeting held on 7th December 2016 were accepted as an accurate record of the meeting but as the meeting was not quorate, these would be ratified at the next meeting.

Action required: -

- Minutes to be ratified at February 2017 meeting.

APC 17/04 MATTERS ARISING AND APC ACTION PLAN

04.1 NICE TA's (October 2016)

Not applicable for use at BHNFT: -

- TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation positive non-small-cell lung cancer

04.2 NICE TA's (November 2016)

Applicable for use at BHNFT: -

- TA288 Updated, Dapagliflozin in combination therapy for treating type 2 diabetes
- TA418 (replaces TA288), Dapagliflflozin in triple therapy for treating type 2 diabetes
- TA419 (replaces TA368), Apremilast for treating moderate to severe plaque psoriasis

Not applicable for use at BHNFT: -

- TA417, Nivolumab for previously treated advanced renal cell carcinoma

Action Plan – Other Areas

04.3 Re-audit of warfarin dose information included on BHNFT discharge letters

This item was due to be discussed at the January 2017 BHNFT Medicines Management Committee meeting.

Agreed action: -

- The Chief Pharmacist, BHNFT to report back from discussions at the BHNFT Medicines Management Committee meeting. **MS**

04.4 GLP-1 Agonists (Exanatide and Liraglutide) Traffic Light Classifications

It was agreed that this would be brought back to the Committee in July 2017 following the reconfiguration of the diabetes nursing service.

04.5 Ticagrelor (Brilique®)

It was confirmed that appropriate processes were in place in all practices and primary care pharmacists were carrying out monthly audits to ensure 12 month end dates were in place. There would be follow up reports to pick up any patient going over the 12 month date. This was a rolling process.

This would be removed from the action plan. **NB**

APC 17/05 RIFAXIMIN

BHNFT would like to request for this drug, currently Amber Shared Care, to change to an Amber G drug.

Initiation, monitoring requirements, review dates and possible interactions were discussed and it was agreed that an Amber G information sheet would be produced. Expected numbers of patients and cost analysis would also be presented to the Committee.

Agreed action: -

- An Amber G information sheet for Rifaximin would be presented at the next meeting, including the expected number of patients and cost analysis. **FH**

APC 17/06 TIOTROPIUM

The Medicines Management Pharmacist, Barnsley CCG presented a summary of the branded generic of tiotropium, Braltus®, highlighting points for consideration.

A number of placebos were demonstrated in the meeting and it was felt Braltus® was slightly easier to use than Spiriva®.

It was suggested that, as a new product, this could possibly be included under the New Medicines Service with training provided by community pharmacists.

The Committee were in favour of switching from Spiriva® to Braltus® but it was agreed that the Medicines Management Pharmacist, Barnsley CCG would check if any other similar products were imminent.

Assurance was requested from BHNFT that they would also undertake the switch but this would need to be costed and fed back to the Committee.

Agreed actions:-

- The Medicines Management Pharmacist, Barnsley CCG would check if any another similar products were imminent. **CA**
- The Medicines Management Pharmacist, Barnsley CCG to contact the Community Pharmacist regarding Braltus® possibly being included under the New Medicines Service. **CA**
- BHNFT costs would be sent to the Medicines Management Pharmacist, Barnsley CCG. **FH/CA**

APC 17/07 NEFOPAM GUIDANCE

A position statement relating to the prescribing of Nefopam was presented and discussed.

There was a query regarding a key point about discontinuing Nefopam post discharge following secondary care acute initiation and it was agreed that the Medicines Management Pharmacist, Barnsley CCG and the Lead Pharmacist, Medicines Information & Cardiology, BHNFT would look at the evidence base for it and discuss this further.

It was suggested that more detail be included under common adverse effects and the Medicines Management Pharmacist, Barnsley CCG agreed to look at this.

Agreed actions

- Medicines Management Pharmacist, Barnsley CCG and the Lead Pharmacist, Medicines Information & Cardiology, BHNFT to look at the evidence base for not continuing Nefopam post discharge following secondary care acute initiation. **CA/FH**
- Medicines Management Pharmacist, Barnsley CCG to look at including further detail under common adverse effects. **CA**
- Following any amendments, the position statement will be emailed to the Committee for approval. **CA**

- Following approval, the position statement will be circulated and for known high prescribing areas, the information would be hand delivered and highlighted to teams/individuals **FH/NH**

APC 17/08 SHARED CARE GUIDELINES

08.1 Shared Care Guideline for Lithium

The shared care guideline for lithium has had a routine update. None of the clinical particulars have changed, the only changes relate to updating of references and dates.

The Committee approved the guidelines.

Action required:-

- Decision to be ratified by full Committee in February 2017. **MG**

08.2 Shared Care Guideline for Olanzapine

The shared care guideline for olanzapine has had a routine update. None of the clinical particulars have changed, the only changes relate to updating of references and dates.

The Committee approved the guidelines.

Action required:-

- Decision to be ratified by full Committee in February 2017. **MG**

08.3 Shared Care Guideline for the use of Pregabalin in treating GAD

There was a request to change the traffic light status from amber to amber G in light of no monitoring requirements but the potential for drug misuse was acknowledged. It was noted and accepted that this was 4th line treatment for generalised anxiety disorders with specialist initiation.

An updated amber G information sheet would be sent to the Medicines Management Pharmacist, Barnsley CCG. **SH/CA**

Action required:-

- Amber G information sheet to be brought back to the February 2017 meeting. **SH**
- Recommendation to be ratified by full Committee in February 2017. **MG**

APC 17/09 NEW PRODUCT APPLICATION LOG

A new product application for Spiolto Respimat® was expected from BHNFT and the Chair reminded the Committee of the requirement for a full declaration of interest to be submitted with the application.

APC 17/10 NEW PRODUCT APPLICATIONS

10.1 Ulipristal Acetate (Esmya®)

The application for Ulipristal Acetate (Esmya®), for intermittent use, was presented to the Committee.

The Committee approved the application, classified red, for use as 2nd line in therapy for intermittent treatment of uterine fibroids.

Action required:-

- Recommendation to be ratified by full Committee in February 2017. **MG**

APC 17/11 BARNSLEYAPCREPORT@NHS.NET FEEDBACK

Enclosure J was received and noted.

Given previous discussions around the reporting process, it was agreed that reports should only be submitted when the NHS number and report category can be supplied.

BAPC17/01/23 & 24 were highlighted and discussed and any issues should be picked up with the practices concerned. **NH**

APC 17/12 NEW NICE TECHNOLOGY APPRAISALS – DECEMBER 2016

The Medicines Management Pharmacist, Barnsley CCG provided drug classifications as follows: -

TA420 Ticagrelor for preventing atherothrombotic events after myocardial infarction – **GREEN, NOTING DIFFERENCE IN DOSE RECOMMENDATIONS**

TA421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy - **ALREADY RED FOR DIFFERENT INDICATION – LINK TO THE NICE TA**

TA422 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer – **RED**

TA423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens – **RED**

TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer – **RED**

TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia – **RED**

TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia - **RED**

12.1 <u>Feedback from BHNFT Clinical Guidelines and Policy Group</u>

No meeting had taken place.

Agreed actions: -

- Feedback to be provided on the applicable use of the December 2016 NICE TA's above. **FH**

12.2 <u>Feedback from SWYPFT NICE Group</u>

It was confirmed that NICE TA420, 421, 422, 423, 424, 425 and 426 were not relevant for use at SWYPFT.

APC 17/13 FEEDBACK FROM THE MEDICINES MANAGEMENT GROUPS

13.1 Primary Care Quality & Cost Effective Prescribing Group
Nefopam prescribing was discussed.

13.2 BHNFT
No meeting had taken place.

13.3 SWYPFT Drugs & Therapeutics Committee (D&TC)
No meeting had taken place.

APC 17/14 ISSUES FOR ESCALATION TO THE QUALITY & PATIENT SAFETY COMMITTEE (Q&PSC)

Agreed action: -

- Nefopam would be escalated to the Q&PSC. **CL/NH**

APC 17/15 HORIZON SCANNING DOCUMENT – DECEMBER 2016

The Committee agreed to classify the new products as follows on the traffic light list (TLL): - **CA**

Hydromorphone 2 mg/mL, 10 mg/mL, 20 mg/mL & 50 mg/mL solution for injection or infusion (Palladone®, Napp Pharmaceuticals) – **ALREADY GREEN ON TLL**
Rosuvastatin (generic) 5 mg, 10 mg, 20 mg and 40 mg film-coated tablets (Rosuvastatin, Aurobindo Pharma – Milpharm) – **ALREADY GREEN ON TLL**
Desmopressin 25 and 50 microgram oral lyophilisate (Noqdirna®, Ferring Pharmaceuticals) – **PROVISIONAL GREY**
Reslizumab 10 mg/mL concentrate for solution for infusion (Cinqaero®▼, Teva Pharmaceuticals) – **PROVISIONAL RED**
Pramipexole 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.10 mg, 2.62 mg and 3.15 mg prolonged-release tablets (Pipexus®, Ethypharm UK) – **ALREADY AMBER ON TLL**
Ustekinumab 130 mg concentrate for solution for infusion (Stelara®, Janssen-Cilag) – **ALREADY RED ON TLL**
Sildenafil 20 mg film-coated tablets (Granpidam®, Accord Healthcare) – **RED**
Etelcalcetide 2.5 mg, 5 mg and 10 mg solution for injection (Parsabiv®▼, Amgen) – **PROVISIONAL RED**
Elbasvir/grazoprevir 50 mg/100 mg film-coated tablets (Zepatier®▼, Merck Sharp & Dohme) – **ALREADY RED ON TLL**
Tibolone (generic) 2.5 mg tablets (Tibolone, Concordia International) – **ALREADY GREEN ON TLL**
Bupivacaine (generic) 2.5 mg/mL and 5 mg/mL solution for injection (Bupivacaine, Aurobindo Pharma – Milpharm) – **PROVISINOAL RED**
Pegaspargase 750 U/mL solution for injection/infusion (Oncaspar®▼, Baxalta) – **ALREADY RED ON TLL**
Irinotecan (pegylated) 5 mg/ml concentrate for solution for infusion (Onivyde®, Baxalta) – **ALREADY RED ON TLL**

APC 17/16 MHRA DRUG SAFETY UPDATE – DECEMBER 2016

The Committee received and noted the December 2016 MHRA Drug Safety Update. The summary of the alert is detailed below: -

1. Cobicistat, ritonavir and coadminsitration with a steroid: risk of systemic corticosteroid adverse effects
   Co-administration of a corticosteroid with an HIV-treatment-boosting agent may increase the risk of adrenal suppression due to a pharmacokinetic interaction.

2. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification
   In light of feedback, clarification on an article, published February 2016, on concomitant use of these medicines in heart failure was provided.

APC 17/17 SOUTH YORKSHIRE AREA PRESCRIBING COMMITTEE MINUTES

The minutes from NHS Doncaster & Bassetlaw CCG (27th October 2016) were received and noted.

APC 17/18 ANY OTHER BUSINESS

18.1 Growth Hormone

The Head of Medicines Optimisation informed the Committee that STH were to embark on a programme of switching all adult patients on growth hormone to the more cost effective equivalent biosimilar of growth hormone called Omnitrope®. The first group of patients that will be approached are those who are receiving their growth hormone via Home Care and the second group to be approached will be those on shared care.

18.2 Palliative Care Drug Stockist Scheme

The Lead Pharmacist, SWYPFT raised an issue with the Palliative Care Drug Stockist Scheme list not being updated following previous suggested changes. It was agreed that the issues would be sent to the Chair. **SH/MG**

APC 17/19 DATE AND TIME OF THE NEXT MEETING

The time and date of the next meeting was confirmed as Wednesday, 8th February 2017 at 12.30 pm in the Boardroom, Hillder House.